Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 2
2005 4
2006 4
2007 1
2009 3
2010 2
2011 1
2012 5
2013 6
2014 6
2015 1
2016 4
2017 5
2018 8
2019 9
2020 8
2021 8
2022 5
2023 5
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

73 results

Results by year

Filters applied: . Clear all
Page 1
Early Prediction of Response Focused on Tumor Markers in Atezolizumab plus Bevacizumab Therapy for Hepatocellular Carcinoma.
Tanabe N, Saeki I, Aibe Y, Matsuda T, Hanazono T, Nishi M, Hidaka I, Kuwashiro S, Shiratsuki S, Matsuura K, Egusa M, Nishiyama N, Fujioka T, Kawamoto D, Sasaki R, Nishimura T, Oono T, Hisanaga T, Matsumoto T, Ishikawa T, Yamasaki T, Takami T. Tanabe N, et al. Among authors: ishikawa t. Cancers (Basel). 2023 May 26;15(11):2927. doi: 10.3390/cancers15112927. Cancers (Basel). 2023. PMID: 37296889 Free PMC article.
Methylated SEPT9 assay-based liquid biopsy as a biomarker in molecular targeted agent-treated hepatocellular carcinoma.
Saeki I, Suehiro Y, Yamauchi Y, Hoshida T, Tanabe N, Oono T, Kawamoto D, Nishimura T, Matsumoto T, Ishikawa T, Shimokawa M, Tamori A, Kawada N, Tamai Y, Iwasa M, Nakagawa H, Nagano H, Takami T, Yamasaki T. Saeki I, et al. Among authors: ishikawa t. Hepatol Int. 2023 Oct;17(5):1289-1299. doi: 10.1007/s12072-023-10488-y. Epub 2023 Apr 25. Hepatol Int. 2023. PMID: 37186217
Status and prospects of liver cirrhosis treatment by using bone marrow-derived cells and mesenchymal cells.
Terai S, Takami T, Yamamoto N, Fujisawa K, Ishikawa T, Urata Y, Tanimoto H, Iwamoto T, Mizunaga Y, Matsuda T, Oono T, Marumoto M, Burganova G, Fernando Quintanilha L, Hidaka I, Marumoto Y, Saeki I, Uchida K, Yamasaki T, Tani K, Taura Y, Fujii Y, Nishina H, Okita K, Sakaida I. Terai S, et al. Among authors: ishikawa t. Tissue Eng Part B Rev. 2014 Jun;20(3):206-10. doi: 10.1089/ten.TEB.2013.0527. Epub 2014 Mar 7. Tissue Eng Part B Rev. 2014. PMID: 24450831 Review.
Timeline for development of autologous bone marrow infusion (ABMi) therapy and perspective for future stem cell therapy.
Terai S, Tanimoto H, Maeda M, Zaitsu J, Hisanaga T, Iwamoto T, Fujisawa K, Mizunaga Y, Matsumoto T, Urata Y, Marumoto Y, Hidaka I, Ishikawa T, Yokoyama Y, Aoyama K, Tsuchiya M, Takami T, Omori K, Yamamoto N, Segawa M, Uchida K, Yamasaki T, Okita K, Sakaida I. Terai S, et al. Among authors: ishikawa t. J Gastroenterol. 2012 May;47(5):491-7. doi: 10.1007/s00535-012-0580-5. Epub 2012 Apr 5. J Gastroenterol. 2012. PMID: 22488349 Review.
Predictors of the Effect of Tolvaptan on the Prognosis of Cirrhosis.
Iwamoto T, Maeda M, Hisanaga T, Saeki I, Fujisawa K, Matsumoto T, Hidaka I, Ishikawa T, Takami T, Sakaida I. Iwamoto T, et al. Among authors: ishikawa t. Intern Med. 2016;55(20):2911-2916. doi: 10.2169/internalmedicine.55.6819. Epub 2016 Oct 15. Intern Med. 2016. PMID: 27746425 Free PMC article.
Double cancer of primary hepatic angiosarcoma and hepatocellular carcinoma treated with atezolizumab plus bevacizumab.
Yamauchi Y, Saeki I, Yamasaki T, Egusa M, Nishiyama N, Fujioka T, Kawamoto D, Nishimura T, Tanabe N, Oono T, Matsumoto T, Ishikawa T, Marumoto Y, Matsukuma S, Shindo Y, Tokumitsu Y, Yoshimine S, Murakami J, Tanaka T, Kimura S, Hoshii Y, Hamano K, Nagano H, Takami T. Yamauchi Y, et al. Among authors: ishikawa t. Hepatol Res. 2023 Jul;53(7):681-686. doi: 10.1111/hepr.13894. Epub 2023 Mar 14. Hepatol Res. 2023. PMID: 36826420
73 results